Showing results (81-90 of 163) with videos related to

Sort By:
Pageof 17
Archives of Medical Research|March 22, 2005
Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patientsDirk Deleu, Leon Aarons, Ikhlas Ali Ahmed
Journal of Clinical Pharmacology|September 5, 2020
Does "Birth" as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full-Term Neonates by Avoiding the Creatinine BiasFarzaneh Salem, Trevor N Johnson, Arran B J Hodgkinson, et al.
Analytical Methods : Advancing Methods and Applications|March 21, 2023
Development of a sensitive biochemical assay for the detection of tofacitinib adherenceStephanie Church, Kimme L Hyrich, Kayode Ogungbenro, et al.
Clinical and Translational Science|November 11, 2025
Translatability of Animal Models for Alzheimer's Disease Using a Machine Learning Based WorkflowAlex Foster-Powell, Guy Meno-Tetang, Amin Rostami-Hodjegan, et al.
British Journal of Clinical Pharmacology|September 17, 2013
Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataNikolaos Tsamandouras, Amin Rostami-Hodjegan, Leon Aarons
CPT: Pharmacometrics & Systems Pharmacology|December 8, 2020
PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual VariabilityHiroyuki Takita, Shelby Barnett, Yueping Zhang, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 13, 2025
Mathematical Modeling of Neuroinflammation in Neurodegenerative DiseasesAlex Foster-Powell, Amin Rostami-Hodjegan, Guy Meno-Tetang, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 11, 2021
Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transportersAmais Ahmad, Kayode Ogungbenro, Annett Kunze, et al.
Clinical Pharmacology and Therapeutics|December 16, 2017
Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and SimulationShelby Barnett, Kayode Ogungbenro, Karelle Ménochet, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 29, 2005
The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease stateEva Parker, Leon Aarons, Malcolm Rowland, et al.
Pageof 17